Formulation Development
Conduit Pharmaceuticals Expands Partnership With Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
Conduit Pharmaceuticals Inc. recently announced that it has entered into an additional license and use agreement with Sarborg Limited to expand the scope of work…
Ethris & Lonza Collaborate to Develop Spray-Dried mRNA Vaccines for Respiratory Disease Prevention
Ethris and Lonza reecently announced a collaboration to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates, designed for mucosal delivery that offer a promising…
ADC PAYLOADS - Progress in Development of Camptothecin-Based ADC Therapeutics
Paul Moore, PhD, Raffaele Colombo, PhD, and Jamie Rich, PhD, say the recent progress in research on novel camptothecin payloads highlights the potential for developing a new generation of ADCs that can overcome some of the limitations of first-generation therapies.
SPECIAL FEATURE - Bioavailability & Solubility: The Promise of Novel Ingredients
Contributor Cindy H. Dubin, speaks with several innovating companies to discuss the use of novel excipients as well as other methods and technologies for tackling bioavailability and solubility once and for all.
FORMULATION FORUM - Lymphatic versus Portal Drug Delivery: An Understanding of Drug Oral Absorption & Food Effect
Jim Huang, PhD, and Shaukat Ali, PhD, say the lymphatic system is a distinctive route that is essential for drug transport and delivery of large and lipophilic molecules by alleviating the challenges in penetrating blood capillaries.
TREND SCOUTING - Anticipating the Future of Pharma
Gregor Deutschle says by implementing a strategic, considerate, and proactive approach to trend forecasting, pharmaceutical service providers can effectively weigh the benefits and challenges of potential trends, invest in those most aligned with customer needs, and avoid the allocation of time and resources in trends that will not provide meaningful ROI.
DRUG DEVELOPMENT - Improving Bioavailability & Solubility in OSDs
Hibreniguss Terefe, PhD, explores the options available to improve bioavailability and solubility and provides guidance to support decision-making when designing oral formulations for poorly soluble drug candidates in early development.
CELL-FREE GENE SYNTHESIS - Eliminating Critical Bottlenecks in Genetic Medicine Development
Marc Unger explores the market trends, challenges, and opportunities new DNA production technologies provide to accelerate genetic advances in healthcare.
EXECUTIVE INTERVIEW - Lonza: Driving Innovation & Sustainability: CDMO Trends & the Future of ADCs
Sebastian Stenderup, Executive Director, Head of Commercial EMEA, Lonza, discusses some of the trends CDMOs are currently facing, from the growth of ADCs to the importance of sustainability, and how his company is responding to them.
EXECUTIVE INTERVIEW - How Vetter’s Expansion of its Senior Management Team Aligns With Prioritization of Strategic Growth
Vetter’s leadership discusses the company’s vision for strategic restructuring, their insights on Contract Development and Manufacturing trends in 2025, and what this strategic change means for the sustainable growth of the company and its global expansion.
ORAL DOSAGE FORMS - The Future of Oral Dosage: Innovations, Challenges & the Path Forward in 2025
Sébastien Croquet explores the latest industry challenges, cutting-edge manufacturing techniques, and patient needs defining today’s oral delivery methods, and breaks down some of the ways drug producers can ride, or even define, the next wave of oral drug delivery.
Gattefossé Advances Animal Health Through Science & Innovation
Gattefossé mission, advancing science for well-being, reflects its core engagement: to provide expert, customized, and responsible solutions in Personal Care and Pharmaceuticals, including animal health.…
MoonLake Secures up to $500 Million in Non-Dilutive Financing From Hercules Capital
MoonLake Immunotherapeutics recently announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in…
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of an Oral Once-Daily Treatment for Obstructive Sleep Apnea
Incannex Healthcare Inc recently announced it has completed Phase 2 patient enrollment in the global Phase 2/3 RePOSA study of IHL-42X for the treatment of…
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial & Advance Regenerative Cell Therapy Pipeline
Neurona Therapeutics, a clinical-stage, privately held biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, today announced the successful completion of an…
Greenwich LifeSciences Announces Positive Immune Response Data From Phase 3 Clinical Trial
Greenwich LifeSciences, Inc. recently announced the following update on FLAMINGO-01 open label immune response data. FLAMINGO-01 Immune Response Data Summary The Company has analyzed the…
Antag Therapeutics Initiates Phase 1a Trial of a First-in-Class GIPR Antagonist to Address Key Gaps in Obesity Treatment
Antag Therapeutics recently announced the initiation of its first-in-human Phase 1 clinical trial evaluating AT-7687, a first-in-class Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist. AT-7687 is…
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
Tiziana Life Sciences, Ltd. recently announced dosing has commenced at Johns Hopkins University (JHU) Autoimmunity Center of Excellence, the third clinical site in its Phase 2…
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval
Denali Therapeutics Inc. recently announced the company’s initiation of a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for…
Atsena Therapeutics Announces $150M to Further Advance Ocular Gene Therapy Programs
Atsena Therapeutics recently announced the successful close of an oversubscribed $150-million Series C financing. The financing was led by Bain Capital’s Life Sciences team, with…
